Download PDF
Synlett 2023; 34(15): 1819-1823
DOI: 10.1055/s-0042-1751456
letter

Nickel-Catalyzed Asymmetric Arylation of H-Phosphinates

Qing Zhang‡
,
Ran-Ran Cui‡
,
Qing-Wei Zhang  ∗
The authors are grateful for financial support from NSFC (22071224), USTC Research Funds of the Double First-Class Initiative (YD2060002010).
› Further Information
    Permissions and Reprints All articles of this category


Abstract

An asymmetric arylation of H-phosphinates with aromatic iodo or bromo compounds, catalyzed by cheap and easily available nickel(II) salts, provides access to P-stereogenic phosphinates. This method features mild reaction conditions and a good functional-group compatibility that includes aniline and phenol derivatives.

Key words

phosphinates - P-stereogenic centers - phosphinates - nickel catalysis - cross-coupling - asymmetric catalysis

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0042-1751456.
  • Supporting Information


Publication History

Received: 18 March 2023

Accepted after revision: 19 April 2023

Article published online:
22 May 2023

© 2023. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

    • 1a Baumgartner T, Réau R. Chem. Rev. 2006; 106: 4681
      CrossrefPubMed
    • 1b Mucha A, Kafarski P, Berlicki Ł. J. Med. Chem. 2011; 54: 5955
      CrossrefPubMed
    • 1c Horsman GP, Zechel DL. Chem. Rev. 2017; 117: 5704
      CrossrefPubMed
    • 1d DiRocco DA, Ji Y, Sherer EC, Klapars A, Reibarkh M, Dropinski J, Mathew R, Maligres P, Hyde AM, Limanto J, Brunskill A, Ruck RT, Campeau L.-C, Davies IW. Science 2017; 356: 426
      CrossrefPubMed
    • 1e Wang M, Zhang L, Huo X, Zhang Z, Yuan Q, Li P, Chen J, Zou Y, Wu Z, Zhang W. Angew. Chem. Int. Ed. 2020; 59: 20814
      CrossrefPubMed
    • 1f Featherston AL, Kwon Y, Pompeo MM, Engl OD, Leahy DK, Miller SJ. Science 2021; 371: 702
      CrossrefPubMed
    • 1g Kahler JP, Verhelst SH. L. RSC Chem. Biol. 2021; 2: 1285
      CrossrefPubMed
    • 2a Korpiun O, Lewis RA, Chickos J, Mislow K. J. Am. Chem. Soc. 1968; 90: 4842
      Crossref
    • 2b Juge S, Genet J. Tetrahedron Lett. 1989; 30: 2783
      Crossref
    • 2c Han L.-B, Zhao C.-Q, Onozawa S.-y, Goto M, Tanaka M. J. Am. Chem. Soc. 2002; 124: 3842
      CrossrefPubMed
    • 2d Berger O, Montchamp J.-L. Angew. Chem. Int. Ed. 2013; 52: 11377
      CrossrefPubMed
    • 2e Maekawa Y, Kuwabara K, Sugiyama A, Iwata K, Maruyama T, Murai T. Chem. Lett. 2017; 46: 1068
      CrossrefPubMed
    • 2f Nie S.-Z, Zhou Z.-Y, Wang J.-P, Yan H, Wen J.-H, Ye J.-J, Cui Y.-Y, Zhao C.-Q. J. Org. Chem. 2017; 82: 9425
      CrossrefPubMed

      For reviews, see:
    • 4a Harvey JS, Gouverneur V. Chem. Commun. 2010; 46: 7477
      CrossrefPubMed
    • 4b Lemouzy S, Giordano L, Hérault D, Buono G. Eur. J. Org. Chem. 2020; 3351
      Crossref

      • For selected examples see:
    • 4c Beaud R, Phipps RJ, Gaunt MJ. J. Am. Chem. Soc. 2016; 138: 13183
      CrossrefPubMed
    • 4d Zhang Y, He H, Wang Q, Cai Q. Tetrahedron Lett. 2016; 57: 5308
      Crossref
    • 4e Dai Q, Li W, Li Z, Zhang J. J. Am. Chem. Soc. 2019; 141: 20556
      CrossrefPubMed
    • 4f Liu X.-T, Zhang Y.-Q, Han X.-Y, Sun S.-P, Zhang Q.-W. J. Am. Chem. Soc. 2019; 141: 16584
      CrossrefPubMed
    • 4g Dai Q, Liu L, Qian Y, Li W, Zhang J. Angew. Chem. Int. Ed. 2020; 59: 20645
      CrossrefPubMed
    • 4h Qiu H, Dai Q, He J, Li W, Zhang J. Chem. Sci. 2020; 11: 9983
      CrossrefPubMed
    • 4i Dai Q, Liu L, Zhang J. Angew. Chem. Int. Ed. 2021; 60: 27247
      CrossrefPubMed
    • 4j Wu Z.-H, Cheng A.-Q, Yuan M, Zhao Y.-X, Yang H.-L, Wei L.-H, Wang H.-Y, Wang T, Zhang Z, Duan W.-L. Angew. Chem. Int. Ed. 2021; 60: 27241
      CrossrefPubMed
    • 4k Cai W.-Q, Wei Q, Zhang Q.-W. Org. Lett. 2022; 24: 1258
      CrossrefPubMed
    • 4l Zhang Y.-Q, Han X.-Y, Wu Y, Qi P.-J, Zhang Q, Zhang Q.-W. Chem. Sci. 2022; 13: 4095
      CrossrefPubMed
    • 5a Harvey JS, Malcolmson SJ, Dunne KS, Meek SJ, Thompson AL, Schrock RR, Hoveyda AH, Gouverneur V. Angew. Chem. Int. Ed. 2009; 48: 762
      CrossrefPubMed
    • 5b Huang Z, Huang X, Li B, Mou C, Yang S, Song BA, Chi YR. J. Am. Chem. Soc. 2016; 138: 7524
      CrossrefPubMed
    • 5c Trost BM, Spohr SM, Rolka AB, Kalnmals CA. J. Am. Chem. Soc. 2019; 141: 14098
      CrossrefPubMed
    • 5d Guo R, Liu Z, Zhao X. CCS Chem. 2021; 3: 2617
      Crossref
    • 5e Huang Q.-H, Zhou Q.-Y, Yang C, Chen L, Cheng J.-P, Li X. Chem. Sci. 2021; 12: 4582
      CrossrefPubMed
    • 5f Song S.-Y, Li Y, Ke Z, Xu S. ACS Catal. 2021; 11: 13445
      Crossref
  • 6 Fu X, Loh W.-T, Zhang Y, Chen T, Ma T, Liu H, Wang J, Tan C.-H. Angew. Chem. Int. Ed. 2009; 48: 7387
    CrossrefPubMed
  • 7 Yang Z, Gu X, Han L.-B, Wang J. Chem. Sci. 2020; 11: 7451
    CrossrefPubMed
  • 8 Zhang Q, Liu X.-T, Wu Y, Zhang Q.-W. Org. Lett. 2021; 23: 8683
    CrossrefPubMed
  • 9 Li Y, Jin X, Liu P, Zhang H, Yu X, Liu Y, Liu B, Yang W. Angew. Chem. Int. Ed. 2022; 61: e202117093
    CrossrefPubMed
  • 10 Wang C, Hu X, Xu C, Ge Q, Yang Q, Xiong J, Duan W.-L. Angew. Chem. Int. Ed. 2023; e202300011
    CrossrefPubMed
  • 11 Zhang Q.-W, Cui R, Hu L, Wang Y, Yuwen L, Gao L, Huang Z, Wang W, Lu G. ChemRxiv 2023; preprint; DOI DOI: 10.26434/chemrxiv2023-p8qvx.
    CrossrefPubMed
  • 12 CCDC 2246563 contains the supplementary crystallographic data for compound 25. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures
  • 13 Diaryl Phosphinates 1–30; General Procedure In a N2-flushed glovebox, a 4 mL vial equipped with a stirrer bar was charged with Ni(acac)2 (2.8 mg, 10 mol%), ligand L2 (4.0 mg, 12 mol%), PhCO2K (32.0 mg, 2.0 equiv), Zn powder (7.8 mg, 1.2 equiv), and EtOAc (0.5 mL), and the mixture was stirred for 10 min. The appropriate H-phosphinate (0.2 mmol) and aryl iodide (0.1 mmol) were added to the vial, which was then capped and removed from the glovebox. The mixture was stirred for 48 h at rt, then purified directly by preparative TLC. Isopropyl (R)-Phenyl(4-tolyl)phosphinate (3) Colorless solid; yield: 25.8 mg (94%, 85% ee); [α]D 20 –3.24 (c = 0.21, acetone). HPLC [Daicel Chiralcel AD-H, hexane–i-PrOH (90:10), 1 mL/min, λ = 254 nm]: t R (major) = 12.17 min, t R (minor) = 13.49 min. 1H NMR (400 MHz, CDCl3): δ = 7.84–7.76 (m, 2 H), 7.75–7.66 (m, 2 H), 7.52–7.46 (m, 1 H), 7.45–7.39 (m, 2 H), 7.25 (dd, J = 8.1, 3.4 Hz, 2 H), 4.72–4.59 (m, 1 H), 2.38 (s, 3 H), 1.34 (dd, J = 6.2, 3.5 Hz, 6 H). 13C NMR (126 MHz, CDCl3): δ = 142.5 (d, J = 3.1 Hz), 132.6 (d, J = 137.7 Hz), 131.8 (d, J = 2.9 Hz), 131.7 (d, J = 10.5 Hz), 131.5 (d, J = 10.1 Hz), 129.2 (d, J = 13.4 Hz), 128.9 (d, J = 139.9 Hz), 128.3 (d, J = 13.2 Hz), 70.1 (d, J = 5.9 Hz), 24.3, 21.6. 31P NMR (162 MHz, CDCl3): δ = 30.2. HRMS (ESI): m/z [M + Na]+ calcd for C16H19NaO2P: 297.1015; found: 297.1021 (S)-Isopropyl(phenyl)(4-tolyl)phosphine Oxide (17) Colorless solid; yield: 13.5 mg (52%; 84% ee); [α]D 20 –12.0 (c = 0.22, acetone). HPLC [Daicel Chiralcel AY-H (84% ee), hexane–i-PrOH (80:20), 1 mL/min, λ = 254 nm]: t R (major) = 10.58 min, t R (minor) = 11.45 min. 1H NMR (500 MHz, CDCl3): δ = 7.81–7.73 (m, 2 H), 7.67 (dd, J = 10.6, 7.9 Hz, 2 H), 7.52–7.42 (m, 3 H), 7.30–7.25 (m, 2 H), 2.57–2.46 (m, 1 H), 2.39 (s, 3 H), 1.21–1.14 (m, 6 H). 13C NMR (126 MHz, CDCl3): δ = 141.9 (d, J = 2.8 Hz), 132.4 (d, J = 94.7 Hz), 131.4 (d, J = 2.7 Hz), 131.0 (d, J = 8.2 Hz), 131.0 (d, J = 8.2 Hz), 129.3 (d, J = 11.5 Hz), 128.7 (d, J = 97.1 Hz), 128.5 (d, J = 11.2 Hz), 27.1 (d, J = 73.0 Hz), 21.5, 15.3 (d, J = 2.2 Hz), 15.2 (d, J = 2.2 Hz). 31P NMR (202 MHz, CDCl3): δ = 37.6. HRMS (ESI): m/z [M + H]+ calcd for C16H20OP: 259.1246; found: 259.1256. 4-[Isopropoxy(phenyl)phosphoryl]phenyl 2-(4-Isobutylphenyl)propanoate (29) Colorless solid; yield: 26.9 mg (58%); [α]D 20 –0.708 (c = 0.24, acetone). 1H NMR (400 MHz, CDCl3): δ = 7.78 (ddd, J = 12.5, 8.0, 6.2 Hz, 4 H), 7.50 (t, J = 7.5 Hz, 1 H), 7.43 (dd, J = 7.7, 3.4 Hz, 2 H), 7.28 (s, 2 H), 7.13 (d, J = 7.8 Hz, 2 H), 7.08 (dd, J = 8.6, 2.6 Hz, 2 H), 4.65 (tt, J = 12.9, 5.9 Hz, 1 H), 3.93 (q, J = 7.1 Hz, 1 H), 2.46 (d, J = 7.2 Hz, 2 H), 1.85 (dq, J = 13.4, 6.7 Hz, 1 H), 1.59 (d, J = 7.1 Hz, 3 H), 1.33 (t, J = 5.7 Hz, 6 H), 0.90 (d, J = 6.6 Hz, 6 H). 13C NMR (126 MHz, CDCl3): δ = 172.7, 153.7 (d, J = 3.3 Hz), 141.0, 136.8, 133.1 (d, J = 11.1 Hz), 132.1 (d, J = 138.6 Hz), 132.0 (d, J = 3.0 Hz), 131.5 (d, J = 10.1 Hz), 129.7 (d, J = 139.2 Hz), 129.6, 128.4 (d, J = 13.1 Hz), 127.1, 121.6 (d, J = 14.0 Hz), 70.4 (d, J = 6.0 Hz), 45.2, 45.0, 30.2, 24.3 (d, J = 3.7 Hz), 22.4, 18.4. 31P NMR (202 MHz, CDCl3): δ = 29.1. HRMS (ESI): m/z [M + H]+ calcd for C28H34O4P: 465.2189; found: 465.2194. Diisopropyl (R,R)-1,4-Phenylenebis[phenyl(phosphinate)] (30) Colorless solid; yield: 21.6 mg (49%, 95% ee); [α]D 20 –1.35 (c = 0.51, acetone).HPLC [Daicel Chiralcel AD-H, hexane–i-PrOH (70:30), 1 mL/min, λ = 254 nm]: t R (major) = 15.94 min, t R (minor) = 9.33 min. 1H NMR (500 MHz, CDCl3): δ = 7.89–7.84 (m, 4 H), 7.83–7.77 (m, 4 H), 7.55–7.50 (m, 2 H), 7.47–7.41 (m, 4 H), 4.72–4.62 (m, 2 H), 1.35 (dd, J = 6.2, 4.8 Hz, 12 H). 31P NMR (202 MHz, CDCl3): δ = 28.5. HRMS (ESI): m/z [M + Na]+ calcd for C24H28NaO4P2: 465.1355; found: 465.1360.